4D Molecular Therapeutics CEO David Kirn's 2021 pay jumps 641% to $5.2M
4D Molecular Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 13, 2022
4D Molecular Therapeutics reported fiscal year 2021 executive compensation information on April 13, 2022.
In 2021, four executives at 4D Molecular Therapeutics received on average a compensation package of $3.3M, a 109% increase compared to previous year.
Average pay of disclosed executives at 4D Molecular Therapeutics
David Kirn, Chief Executive Officer, received $5.2M in total, which increased by 641% compared to 2020. 84% of Kirn's compensation, or $4.4M, was in option awards. Kirn also received $228K in non-equity incentive plan, $570K in salary, as well as $13K in other compensation.
August Moretti, Chief Financial Officer, received a compensation package of $2.6M, which increased by 317% compared to previous year. 78% of the compensation package, or $2M, was in option awards.
August J. Moretti, Chief Financial Officer, earned $2.6M in 2021.
Theresa Janke, Chief of Staff, received $2.6M in 2021.
Related executives
You may also like
Source: SEC filing on April 13, 2022.